BBIO
BridgeBio Pharma, Inc.Company with tickers: BBIO
Market Cap
$13.91B
Shares Outstanding
195,861,242
CIK
1743881
CUSIP
10806X102
13F Activity (30d)
3 filings
2 filers
Website
Visit website
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Hannah A. Valantine | Class I director | Appointed | 2026-06-26 |
| Frank P. McCormick | Class I director | Appointed | 2026-06-26 |
| James C. Momtazee | Class I director | Appointed | 2026-06-26 |
| Randal W. Scott | member of the Board of Directors | Resigned | 2026-06-26 |